Last updated on July 2019

Study to Evaluate the Efficacy Safety and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)


Brief description of study

This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).

Clinical Study Identifier: NCT03977155

Find a site near you

Start Over

Synexus Clinical Research US, Inc.

Anderson, SC United States
9.42miles
  Connect »